Lemaitre Vascular Inc. (LMAT) intrinsic value & 10-year financials

Lemaitre Vascular Inc. (LMAT) has a Graham intrinsic value of $83.70 per share. At $80.82 on Oct 17, 2026, the stock trades 3% below that value. Over the last 10 fiscal years revenue grew 12.1% a year to $249.6M, with an average return on invested capital of 13.4%.

Graham intrinsic value
$83.70
Share price (Oct 17, 2026)
$80.82
Price vs Graham value
3% below
Market cap
$1.9B
Revenue (FY2025)
$249.6M
Revenue growth (10-yr CAGR)
12.1%
ROIC (10-yr avg)
13.4%
Free cash flow (FY2025)
$74.5M

LMAT 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $249.6M $57.7M $2.52 $74.5M 27.2% 14.8%
FY2024 $219.9M $44.0M $1.93 $37.2M 23.8% 13.1%
FY2023 $193.5M $30.1M $1.34 $29.5M 19.0% 10.1%
FY2022 $161.7M $20.6M $0.93 $22.1M 16.6% 7.8%
FY2021 $154.4M $26.9M $1.25 $30.2M 23.6% 13.8%
FY2020 $129.4M $21.2M $1.04 $31.8M 22.3% 14.4%
FY2019 $117.2M $17.9M $0.88 $10.4M 18.1% 11.7%
FY2018 $105.6M $22.9M $1.13 $16.5M 26.7% 19.0%
FY2017 $100.9M $17.2M $0.86 $16.5M 20.9% 17.4%
FY2016 $89.2M $10.6M $0.55 $14.1M 18.3% 12.2%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

LEMAITRE VASCULAR INC is a consistent compounder, expanding top-line revenue at 12.1% annually over the past decade.

LEMAITRE VASCULAR INC returns on capital have been average, hovering around 13.4% ROIC over the decade.

LEMAITRE VASCULAR INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, LEMAITRE VASCULAR INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $83.70 per share.

LMAT stock: frequently asked questions

What is the intrinsic value of Lemaitre Vascular Inc. (LMAT) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 15.0% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, LMAT's intrinsic value is about $83.70 per share.

Is LMAT stock undervalued?

At $80.82 (close on Oct 17, 2026), LMAT trades 3% below its Graham value of $83.70. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Lemaitre Vascular Inc. grown?

Revenue went from $89.2M in fiscal 2016 to $249.6M in fiscal 2025, a compound annual growth rate of 12.1%. Net income was $57.7M in fiscal 2025.

Does Lemaitre Vascular Inc. generate free cash flow?

Lemaitre Vascular Inc. generated $74.5M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 10 of the last 10 reported years.

What is LMAT's return on invested capital?

Average ROIC over the last 10 fiscal years was 13.4%, and average return on equity was 13.6%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this LMAT data come from?

From Lemaitre Vascular Inc.'s annual 10-K filings on SEC EDGAR. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar surgical & medical instruments & apparatus stocks